Takeda Pharmaceutical (TKPHF) EPS (Weighted Average and Diluted) (2017 - 2026)

Takeda Pharmaceutical's EPS (Weighted Average and Diluted) history runs 10 years deep, the most recent figure standing at -$203.3 million for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) fell 104.94% year-over-year to -$203.3 million; the TTM figure through Mar 2026 stood at -$203.3 million (down 104.94% YoY), while the FY2026 annual figure was $1.6 billion, up 363160610376.92% from the prior year.
• EPS (Weighted Average and Diluted) was -$203.3 million for Q1 2026 at Takeda Pharmaceutical, down from $1.0 billion in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $9.9 billion in Q3 2025 to a low of -$203.3 million in Q1 2026.
• Historically, EPS (Weighted Average and Diluted) has averaged $2.5 billion across 5 years, with a median of $1.6 billion in 2022.
• The sharpest annual moves came in 2022 and 2025: EPS (Weighted Average and Diluted) sank 109.44% in 2022, then soared 12536.21% in 2025.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $652.2 million in 2022, then soared by 161.99% to $1.7 billion in 2023, then slumped by 49.69% to $859.6 million in 2024, then advanced by 21.04% to $1.0 billion in 2025, then slumped by 119.54% to -$203.3 million in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$203.3 million (Q1 2026), $1.0 billion (Q4 2025), and $9.9 billion (Q3 2025), per Business Quant data.